

| HPV Primary Screening Update to “Best Care HPV” Mōhio Form | | | | | | | | | | | | | | | | | |
|---|--|---------------------|----------|------------------------|---------------------|-------------------------------|---|------|---|---|------|---|---|------|--------------------|---|------|
| Prepared by | Ashley Hulme – Chief Operations Officer Siobhan Matich – Clinical and Quality Manager | | | | | | | | | | | | | | | | |
| Endorsed by | Auckland PHO Senior Management Team | | | | | | | | | | | | | | | | |
| For the attention of: | GPs, Nurse Practitioners and Practice Nurses | | | | | | | | | | | | | | | | |
| Date of update | Tuesday 12 November 2024 | | | | | | | | | | | | | | | | |
| Background | <p>The recently updated “Best Care HPV” Mōhio Form has undergone a revision. The changes are:</p> <ol style="list-style-type: none"> 1. Correction to the eligibility criteria for underscreened and unscreened group 2. Updates to the funding eligibility criteria made by Te Whatu Ora post the October 1st programme launch. <p>For more information on the programme funding and eligibility criteria, refer to the Auckland PHO website Resource Library document, along with Te Whatu Ora information and Auckland Regional HealthPathways (links below).</p> | | | | | | | | | | | | | | | | |
| Links and resources | <ul style="list-style-type: none"> • Te Whatu Ora HPV Primary Screening Funding Document • Te Whatu ora HPV Primary Screening Eligibility Criteria • Te Whatu Ora Clinical Practice Guidelines for Cervical Screening (updated June 2023) • Auckland Regional HealthPathways – Cervical Screening • Auckland PHO Programme Library Guide | | | | | | | | | | | | | | | | |
| Auckland PHO contact | For queries contact Siobhan Matich siobhan@aucklandpho.co.nz | | | | | | | | | | | | | | | | |
| Updated Mōhio Best Care HPV Form | | | | | | | | | | | | | | | | | |
| Summary | <p>The <i>Mōhio Best Care HPV Form</i> has been updated to include:</p> <ul style="list-style-type: none"> • Changes in eligibility and funding - for people who are due for either CX or HPV, are funded if they meet the eligibility criteria • Integration of NCSP data for the latest results <p>Eligibility and Funding Table</p> <table border="1"> <thead> <tr> <th>Category</th> <th>Population Description</th> <th>Claim Fee (ex. GST)</th> </tr> </thead> <tbody> <tr> <td>HPV Self-Test Priority Groups</td> <td>People who are due for screening and are: <ul style="list-style-type: none"> • Aged between 25-69 years, and who are • Māori, Pacific or CSC holder </td> <td>\$50</td> </tr> <tr> <td>Unscreened & Under-screened HPV Self-Test</td> <td>People who are: <ul style="list-style-type: none"> • Aged 30 years and over, and who are • Māori, Pacific </td> <td>\$60</td> </tr> <tr> <td>Unscreened & Under-screened HPV Self-Test</td> <td>People who are: <ul style="list-style-type: none"> • Aged 30 years and over, and who are • non-Māori, non-Pacific </td> <td>\$50</td> </tr> <tr> <td>Follow-Up Cytology</td> <td>Any enrolled patient meeting the following criteria: <ol style="list-style-type: none"> 1. Follow up after HPV Other 2. 1-year follow up after LG (or LSIL) cytology (Co-test) prior to 12.09.2023 3. After an Invalid Test 4. Needs TOC (Test of Cure) (Co-test) after colposcopy 5. On Annual Co-Test (Ann) (Co-test for life) </td> <td>\$72</td> </tr> </tbody> </table> | | Category | Population Description | Claim Fee (ex. GST) | HPV Self-Test Priority Groups | People who are due for screening and are: <ul style="list-style-type: none"> • Aged between 25-69 years, and who are • Māori, Pacific or CSC holder | \$50 | Unscreened & Under-screened HPV Self-Test | People who are: <ul style="list-style-type: none"> • Aged 30 years and over, and who are • Māori, Pacific | \$60 | Unscreened & Under-screened HPV Self-Test | People who are: <ul style="list-style-type: none"> • Aged 30 years and over, and who are • non-Māori, non-Pacific | \$50 | Follow-Up Cytology | Any enrolled patient meeting the following criteria: <ol style="list-style-type: none"> 1. Follow up after HPV Other 2. 1-year follow up after LG (or LSIL) cytology (Co-test) prior to 12.09.2023 3. After an Invalid Test 4. Needs TOC (Test of Cure) (Co-test) after colposcopy 5. On Annual Co-Test (Ann) (Co-test for life) | \$72 |
| Category | Population Description | Claim Fee (ex. GST) | | | | | | | | | | | | | | | |
| HPV Self-Test Priority Groups | People who are due for screening and are: <ul style="list-style-type: none"> • Aged between 25-69 years, and who are • Māori, Pacific or CSC holder | \$50 | | | | | | | | | | | | | | | |
| Unscreened & Under-screened HPV Self-Test | People who are: <ul style="list-style-type: none"> • Aged 30 years and over, and who are • Māori, Pacific | \$60 | | | | | | | | | | | | | | | |
| Unscreened & Under-screened HPV Self-Test | People who are: <ul style="list-style-type: none"> • Aged 30 years and over, and who are • non-Māori, non-Pacific | \$50 | | | | | | | | | | | | | | | |
| Follow-Up Cytology | Any enrolled patient meeting the following criteria: <ol style="list-style-type: none"> 1. Follow up after HPV Other 2. 1-year follow up after LG (or LSIL) cytology (Co-test) prior to 12.09.2023 3. After an Invalid Test 4. Needs TOC (Test of Cure) (Co-test) after colposcopy 5. On Annual Co-Test (Ann) (Co-test for life) | \$72 | | | | | | | | | | | | | | | |

| | | |
|---|---|------------|
| HPV 16 & 18 Result (Referred to Colposcopy) | Any person with this result needs contacting with results discussion, and needs to be referred to colposcopy. | \$50 |
| Routine Screening | Routine screening for all other populations not mentioned above | Not funded |

Integration of NCSP data for the latest results

NCSP Data has been included in the *Mōhio Best Care HPV Form* to assist confirmation of “due” and “next scheduled” event. The NCSP data provides an update twice monthly on:

1. Latest test result date
2. Latest result
3. Next expected event due date
4. Next expected event

Overview of the Mohio Form

Below is a screenshot of the updated *Mōhio Best Care HPV Form*

The updated *Mōhio Best Care HPV Form* is found in the same location on the Mōhio Forms Menu:

- AUCKLAND PHO PROGRAMMES AND SERVICES
 - o AFX and CHA2DS2-VASc score
 - o Alcohol SBI
 - o Best Care HPV
 - o Bowel Screening Referral


Integration of NCSP CX and HPV data

NCSP data is updated twice monthly from the practice report. This will assist in confirming the screening due date and next event.

Claiming category and eligibility

The HPV CX Claim Types have not changed. Note one claim per screening test, and under only one category.


HPV Claim Type



i. HPV self-test priority groups

- Māori, Pacific or CSC Card Holders 25-69 years due for screening.

HPV Claim Type



HPV Self-Test and Co-Test Funding Eligibility

- Priority Populations: Aged 25-69 years Māori or Pacific or CSC Card Holder

ii. Self-test under-screened and un-screened:

- Unscreened and Under-screened 30-74 years

Definitions


Under-screened

- Women and people with a cervix aged 30 to 69 years; and it has been:
 - Five years or more (three years or more if immune deficient) from their previous normal cytology screen.
 - Seven years or more (five years or more if immune deficient) since their last normal HPV test.
- Women and people with a cervix aged 70 to 74 years who have not had:
 - Two consecutive normal cervical cytology results between age 62 to 69 years, OR
 - A 'HPV not detected' result between age 65 to 69 years.

Unscreened

- Women and people with a cervix aged 30 to 74 years who have never been screened for cervical cancer.

HPV Claim Type



HPV Self-Test and Co-Test Funding Eligibility (No Copay)

- Aged 30 years & over unscreened or underscreened Māori, Pacific
- Aged 30 years & over unscreened or underscreened Non-Māori, Non-Pacific

Special Note - Ordering Co-Tests:

Liquid Based Cytology Co-Test is funded for some eligible groups and requires specific e-labs detail in order to get both the HPV Test and Liquid based cytology test performed by the lab.

Ensure Co-Test at the top of the e-labs form is ticked and provide details of the history supporting request for a Co-Test otherwise only HPV Testing will be completed. For example, TOC1 or TOC2; symptomatic, history of abnormalities.

iii. Co-test pre-existing abnormalities

Liquid Based Cytology Co-Test funding eligibility criteria:

- Unscreened & Underscreened needing a Cotest (30-74 years old)
- Priority Groups needing a Cotest (25-69 years old)
- 25-69 years needing a co-test non-Māori, Non Pacific or non-CSC Card holders

Note – On the E-Labs Form, tick Co-Test and provide details of history supporting request for a Co-Test otherwise only HPV Testing will be completed. For example, TOC1 or TOC2.

HPV Claim Type

Co-test pre-existing abnormalities

HPV Self-Test and Co-Test Funding Eligibility (No Copay)

- Aged 30 years & over unscreened or underscreened Māori, Pacific
- Aged 30 years & over unscreened or underscreened Non-Māori, Non-Pacific
- Priority Populations: Aged 25-69 years Māori or Pacific or CSC Card Holder
- Aged 25-69 years Non-Māori, Non-Pacific, Non-CSC needing a CoTest
- Aged 70-74 years from all ethnicities needing a CoTest, if not covered by the options listed above

iv. Cytology follow-up (for specific groups only) eligibility criteria:

- Follow-up after HPV Other
- One year follow-up after LG or LSIL cytology result
- After an invalid test
- Test of Cure needed (TOC1 or TOC2) following discharge from colposcopy
- On Annual Co-Test (Ann) (Co-test for life)


HPV Claim Type

Cytology follow-up

Funded with \$72+GST if the patient meets at least one of the Funding Eligibility criteria below.

HPV Follow-up Cytology (LBC) Eligibility (No Copay)

- Recommended HPV and / or cytology follow-up testing after 'HPV Other' detected
- A person who has not returned to the standard screening intervals at 12th September 2023 and require follow-up testing (i.e., Previous test result was 'invalid' or 'unsuitable for analysis test result' or 'unsatisfactory cytology result')
- Repeat cytology after 'invalid' or 'unsuitable for analysis test result' or 'unsatisfactory cytology result'
- 'Test of Cure' because of history of high grade result; or recommended Follow-up after colposcopy
- Annual co-testing (for life) because of previous HPV-negative high-grade cervical or vaginal lesions, or history of adenocarcinoma in situ
- Patient requested LBC after Colp referral for HPV 16/18, additional result sent to Colp

| | |
|---|---|
| | <p>v. HPV 16 & 18 Result requiring Referral to Colposcopy</p> <ul style="list-style-type: none"> • Aged 30 years & over unscreened or underscreened Māori, Pacific • Aged 30 years & over unscreened or underscreened Non-Māori, Non-Pacific • Priority Populations: Aged 25-69 years Māori or Pacific or CSC Card Holder • Aged 25-69 years Non-Māori, Non-Pacific needing a CoTest • Aged 70-74 years from all ethnicities needing a CoTest, if not covered by the options listed above <p>HPV Claim Type Self-test HPV 16 & 18 positive refer ▼</p> <p style="background-color: #fff9c4; padding: 5px;">Funded with \$50+GST based on the Funding Eligibility criteria selected below.</p> <p>HPV Self-Test and Co-Test Funding Eligibility (No Copay)</p> <ul style="list-style-type: none"> <input type="checkbox"/> Aged 30 years & over unscreened or underscreened Māori, Pacific <input type="checkbox"/> Aged 30 years & over unscreened or underscreened Non-Māori, Non-Pacific <input type="checkbox"/> Priority Populations: Aged 25-69 years Māori or Pacific or CSC Card Holder <input type="checkbox"/> Aged 25-69 years Non-Māori, Non-Pacific, Non-CSC needing a CoTest <input type="checkbox"/> Aged 70-74 years from all ethnicities needing a CoTest, if not covered by the options listed above |
| <p>Reasons for repeat test</p> | <p>There are no changes to the list of reasons for repeat test:</p>  |
| <p>Disclaimers and Attachments</p> | <p>Disclaimers</p> <ul style="list-style-type: none"> • “At present, there is not an HPV recall in place on this form. Please ensure that a recall is set properly once the test result is received.” • “Symptomatic group only funded if CX/HPV within 6months of due date” <p>If the patient wishes to withdraw from the screening programme, the following link is embedded in the form: Withdrawing from the National Cervical Screening Programme (mohio.co.nz)</p> |